Healthcare Providers and Services
Company Overview of ARUP Laboratories, Inc.
ARUP Laboratories, Inc. operates a clinical and anatomic pathology reference laboratory in the United States. It offers ATOP, a laboratory analytics service to identify over-, under-, and mis-utilization of individual laboratory tests; ARUP Connect, an online information system for referral test management that enables to access test results, submit statistical data, and retrieve files; and ARUP Consult, a guide on PDA and Web platforms to assist the clinician with laboratory test selection and interpretation. The company also provides ARUP Direct, a start-to-finish outreach program to help clients; ARUP Gateway, an integrated customer test menu tool to serve the client's outreach medical co...
500 Chipeta Way
Salt Lake City, UT 84108-1221
Founded in 1984
Key Executives for ARUP Laboratories, Inc.
Chief Executive Officer and President
Chief Operating Officer and Executive Vice President of Corporate Communications
Senior Technical Vice President
Administrative Vice President and Medical Director of Animal Reference Pathology Laboratory
Senior Vice President and Director of Marketing
Compensation as of Fiscal Year 2014.
ARUP Laboratories, Inc. Key Developments
ARUP Laboratories Adds Prosigna to its Test Menu
Mar 5 14
ARUP Laboratories announced on March 3, that it has added the Prosigna Breast Cancer Prognostic Gene Signature assay to its comprehensive suite of breast cancer diagnostic tests. This assay is FDA 510(k) cleared for node-negative (stage I or II) or node-positive (stage II), hormone receptor-positive (HR+) breast cancer patients. Prosigna provides an individualized assessment of a patient's risk of recurrence at ten years given endocrine therapy alone. The test uses the biology of the tumor and clinical variables to assess risk and has shown improved prognostic accuracy over other breast cancer tests on the market. The University of Utah and the Huntsman Cancer Institute in Salt Lake City were integral in developing the 50-gene expression signature. Dr. Philip Bernard, a co-inventor of the test and medical director of molecular oncology diagnostics at ARUP Laboratories, oversees the test and can provide additional consultation through ARUP Client Services.
ARUP Laboratories, Inc. Appoints Jerry W. Hussong as Chief Medical Officer and Director of Laboratories Replaces Sherrie Perkins
Jul 11 13
ARUP Laboratories, Inc. announced the appointment of Jerry W. Hussong, MD, as chief medical officer (CMO) and director of laboratories, effective, July 1, 2013. Hussong will be taking over the responsibility from Sherrie Perkins, MD, PhD. Perkins will transition into senior vice president, research and development; co-executive director, ARUP Institute for Clinical and Experimental Pathology; and division head of clinical pathology in the Department of Pathology at the University of Utah School of Medicine.
Predictive Biosciences Announces Partnership with ARUP Laboratories
Apr 2 13
Predictive Biosciences, Inc. announced a partnership with ARUP Laboratories, Inc. to offer the company's molecular diagnostic bladder cancer tests to ARUP's national network of clients. Through a non-exclusive agreement, ARUP will offer Predictive's CertNDx(TM) Bladder Cancer Assays in its comprehensive test menu to hospitals, healthcare providers, academic medical centers and military and government facilities around the country. ARUP's clients will be able to order CertNDx testing, submit samples and receive all results through ARUP. Predictive Biosciences will run the diagnostic testing in its CAP and CLIA-certified laboratory. The CertNDx Bladder Cancer Assay is a non-invasive, urine-based test to assess patients with hematuria and to monitor for bladder cancer recurrence post treatment. The test's unique approach stratifies patients based on their likelihood of bladder cancer and is highly accurate across all stages and grades of bladder cancer. CertNDx testing is also available in a tissue-based prognostic test for molecular grading that can provide a quantitative molecular assessment of tumor grade including the likelihood of disease progression.
Similar Private Companies By Industry
Recent Private Companies Transactions
|No transactions available in the past 12 months.|